Key result
Intravenous administration of alpha-tocopherol-conjugated heteroduplex oligonucleotide (Toc-HDO) efficiently silenced target genes in lymphocytes and significantly ameliorated clinical symptoms in mouse models of experimental autoimmune encephalomyelitis.
Why the study?
Efficient in vivo delivery of oligonucleotide therapy to lymphocyte populations remains a challenge for treating autoimmunity, inflammation, and cancer.
Does intravenous Toc-HDO improve target gene silencing in lymphocytes and ameliorate EAE symptoms in mouse models compared to ASO?
Does intravenous Toc-HDO improve target gene silencing in lymphocytes and ameliorate EAE symptoms in mouse models compared to ASO?
Toc-HDO provides a highly efficient and safe in vivo delivery platform for gene silencing in lymphocytes, offering a potential therapeutic strategy for immune-mediated diseases.
Answers are grounded in this paper and cite their sources.
May advance lymphocyte-targeted silencing in EAE models; leaves open translation to human autoimmune therapies.
Manipulating lymphocyte functions with gene silencing approaches is promising for treating autoimmunity, inflammation, and cancer. Although oligonucleotide therapy has been proven to be successful in treating several conditions, efficient in vivo delivery of oligonucleotide to lymphocyte populations remains a challenge. Here, we demonstrate that intravenous injection of a heteroduplex oligonucleotide (HDO), comprised of an antisense oligonucleotide (ASO) and its complementary RNA conjugated to α-tocopherol, silences lymphocyte endogenous gene expression with higher potency, efficacy, and longer retention time than ASOs. Importantly, reduction of Itga4 by HDO ameliorates symptoms in both adoptive transfer and active experimental autoimmune encephalomyelitis models. Our findings reveal the advantages of HDO with enhanced gene knockdown effect and different delivery mechanisms compared with ASO. Thus, regulation of lymphocyte functions by HDO is a potential therapeutic option for immune-mediated diseases.
No takes yet. Share an insight, caveat, or question.
Ohyagi et al. (2021) studied Experimental autoimmune encephalomyelitis (EAE) and Graft-versus-host disease (GVHD). alpha-tocopherol-conjugated heteroduplex oligonucleotide (Toc-HDO) vs. Antisense oligonucleotide (ASO) or PBS was evaluated on Target gene expression and clinical EAE score. Intravenous administration of alpha-tocopherol-conjugated heteroduplex oligonucleotide (Toc-HDO) efficiently silenced target genes in lymphocytes and significantly ameliorated clinical symptoms in mouse models of experimental autoimmune encephalomyelitis.
Synapse has enriched 10 related papers. Consider them for comparative context: